Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Chiesi Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Chiesi Ventures

Chiesi Ventures

Operating

Chiesi Ventures: A US-based venture capital firm investing in early-stage healthcare, focusing on rare disorders.

Location
Boston, MA, US
Founded
2014
Firm
Compare
Portfolio
Employees
Website

Chiesi Ventures is a US-based venture capital firm specializing in early-stage investments within the healthcare sector, with a particular focus on rare and orphan disorders. The firm typically participates in Series A, Series B, and occasionally Series C funding rounds, aligning its investments to complement the strategic interests of the Chiesi Group.

Notable portfolio companies include 4D Molecular Therapeutics, CuraSen Therapeutics, Glycomine, Kezar Life Sciences, Mirum Pharmaceuticals, Sentien Biotechnologies, Sentieon, and VelosBio. Chiesi Ventures engages deeply with the scientific community, industry stakeholders, and regulators to navigate the complexities of developing cures for rare diseases. Their investment philosophy centers on fostering innovation and accelerating diagnosis and treatment for rare conditions.

Chiesi Ventures - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments11
Current Portfolio Count7
Total Portfolio Exits1

Top Investment Stages

Series A6 (54.5%)
Series B4 (36.4%)
Series C1 (9.1%)

Stage Mix

Series A 55%Series B 36%Series C 9%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Glycomine logo

Glycomine

4D Molecular Therapeutics logo

4D Molecular Therapeutics

Mirum Pharmaceuticals logo

Mirum Pharmaceuticals

CuraSen Therapeutics logo

CuraSen Therapeutics

VelosBio logo

VelosBio

Kezar Life Sciences logo

Kezar Life Sciences

Sentien Biotechnologies logo

Sentien Biotechnologies

Sentieon logo

Sentieon

Chiesi Ventures - Similar Investment Firms

Healthcare Ventures logo

Healthcare Ventures

hcven.com

CHV Capital logo

CHV Capital

chvcapital.com

Versant Ventures logo

Versant Ventures

DaVita Venture Group logo

DaVita Venture Group

Optum Ventures logo

Optum Ventures

optumventures.com

NeuroVentures Capital logo

NeuroVentures Capital

neuroventures.com

McKesson Ventures logo

McKesson Ventures

Nest.Bio Venture logo

Nest.Bio Venture

nest.bio

Endpoint Ventures logo

Endpoint Ventures

endpoint.vc

Bioventures Investors logo

Bioventures Investors

Pfizer Venture Investments logo

Pfizer Venture Investments

pfizer.com

CureDuchenne Ventures logo

CureDuchenne Ventures

cureduchenne.org

Pathway to Cures logo

Pathway to Cures

pathwaytocures.org

Inbio Ventures logo

Inbio Ventures

Venture Investors logo

Venture Investors

Chiesi Ventures - Classification

Also Known As
  • Chiesi Ventures, Inc.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end